控制释放的技术Diltiazem化:一个全面的审查固体剂量创新
Estefanía Troches-Mafla1, Constain H Salamanca2,3,4, Yhors Ciro1
1Grupo de Investigación en Química y Biotecnología (QUIBIO), Facultad de Ciencias Básicas, Universidad Santiago de Cali, Cali 760035, Colombia.
Pharmaceutics
|November 27, 2025
概括
丁胺的修改释放剂型 (MRDF) 通过优化药物释放来改善患者的坚持. 先进的配方策略和建模提高了药物动力学特征和临床结果.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 药理动力学 药理动力学
背景情况:
- 作为通道阻塞剂的迪尔提亚泽姆化 (DH) 因其短半衰期而面临挑战,导致患者的坚持不良和血度波动.
- 修改释放剂型 (MRDF) 为克服这些局限性提供了一个解决方案.
研究的目的:
- 批判性地审查最新的制药技术和DHMRDFs的配方策略.
- 评估它们对药理动力学,临床性能和监管合规性的影响.
主要方法:
- 使用主要科学数据库进行了从2010年至2025年的结构化文献综述.
- 研究的重点是DH的固体口服MRDF和相关制造技术.
主要成果:
- 各种技术 (例如,挤出-球体化,喷雾干燥) 已经产生了水友性矩阵,涂层颗粒,微球和透系统.
- 功能性聚合物 (HPMC,Eudragit®,乙基纤维素) 是控制释放动力学和生物可用性的关键.
结论:
- 目前用于DHMRDFs的配方策略已被合成.
- 像PBPK建模和IVIVC这样的先进工具支持针对个性化,符合监管的疗法的合理设计.
相关概念视频
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K
Drug Delivery: Enteral Route
1.5K
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
1.5K
In Vitro Drug Dissolution: Alternative Methods
182
Alternative drug dissolution methods include the rotating bottle, intrinsic dissolution test, peristalsis, and the Franz diffusion cell method. The rotating bottle method involves meticulously rotating tightly capped controlled-release beads in a temperature-controlled bath. Periodic decanting of samples allows for residue assay, followed by refilling with fresh medium and testing at various pH levels to emulate the gastrointestinal tract conditions.In contrast, the intrinsic dissolution test...
182
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
185
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
185
Antihypertensive Drugs: Thiazide-Class Diuretics
1.6K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
1.6K
In Vitro Drug Release Testing: Overview, Development and Validation
291
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
291


